The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb; Eisai
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Karus Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Celgene; Eisai
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck (Inst); Nutide (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Verastem (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Sarah Patricia Blagden
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I)
Speakers' Bureau - Clovis Oncology; OCTIMET
Research Funding - Incyte (Inst); Nucana (Inst); octimet (Inst); Piqur (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1
Travel, Accommodations, Expenses - Nucana; Tesaro
 
Janet Shirley Graham
No Relationships to Disclose
 
Kristen Keon Ciombor
Consulting or Advisory Role - Bayer
Research Funding - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Sanofi (Inst)
 
Aimery De Gramont
Honoraria - Chugai Pharma; Yakult Pharmaceutical
 
Josep Tabernero
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Genentech/Roche; Lilly; Merck Serono; MSD; Novartis; Roche; Sanofi; Symphogen; Taiho Pharmaceutical
 
Jordan Berlin
Honoraria - genentech; Nestle health science
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; BeiGene; Celgene; Cornerstone Pharmaceuticals; Eisai; EMD Serono; ERYTECH Pharma; Exelixis; Five Prime Therapeutics; Genentech/Roche; Gritstone Bio; Karyopharm Therapeutics; Symphogen
Research Funding - Bayer (Inst); BeiGene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Loxo (Inst); Pharmacyclics (Inst); symphogen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Abbvie; EMD Serono; Genentech/Roche; Nestle health science
Other Relationship - AstraZeneca